{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:11:04Z","timestamp":1772118664238,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Second allogeneic stem cell transplantation (allo\u2010SCT2) represents a rescue option for selected patients (pts) with relapsed\/refractory (r\/r) acute myeloid leukemia (AML). Still, relapse rates post\u2010allo\u2010SCT2 remain high and effective anti\u2010relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo\u2010SCT2 in our center. Allo\u2010SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non\u2010relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo\u2010SCT2. Addressing relapse after allo\u2010SCT2, 14 pts (74%) underwent cell\u2010based anti\u2010relapse strategies, including third allogeneic transplantation (allo\u2010SCT3; 3\/14), donor lymphocyte infusions (DLIs) combined with either 5\u2010azacytidin and venetoclax (4\/14) or chemotherapeutic agents (7\/14). Notably, six of seven pts (86%) who received either allo\u2010SCT3 or a combination therapy of DLIs, 5\u2010azacytidine and venetoclax achieved CR despite poor cytogenetics post\u2010allo\u2010SCT2 (e.g.,\n                    <jats:italic>TP53<\/jats:italic>\n                    ). Finally, 11 of 41 pts were alive at the last follow\u2010up (seven CR2, three CR3, one partial remission) resulting in estimated 2\u2010 and 5\u2010year overall survival of 35% and 25%, respectively.\n                  <\/jats:p>","DOI":"10.1002\/hon.2995","type":"journal-article","created":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T06:14:16Z","timestamp":1648966456000},"page":"763-776","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes of second allogeneic stem cell transplantation and anti\u2010relapse strategies in patients with relapsed\/refractory acute myeloid leukemia: A unicentric retrospective analysis"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-1729","authenticated-orcid":false,"given":"Evgenii","family":"Shumilov","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"},{"name":"Department of Medicine A, Hematology, Oncology and Pneumology University Hospital M\u00fcnster  M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Maulhardt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Mazzeo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hristo","family":"Boyadzhiev","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Ganster","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-5685","authenticated-orcid":false,"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Medicine G\u00f6ttingen (UMG)  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16355"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.10"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.023"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2091"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.012"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0584-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7961"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0251-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.186"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704645"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.10.006"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.267"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0125-6"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3675"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.068"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2739"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.2906.2906"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.03.019"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004"},{"issue":"6","key":"e_1_2_10_24_1","first-page":"825","article-title":"Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0204-7"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2247.2247"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1755-7"},{"key":"e_1_2_10_28_1","article-title":"Feasibility of venetoclax\u2010based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation","volume":"54","author":"Moukalled N","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188094"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242826"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.608"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000"},{"issue":"2437","key":"e_1_2_10_33_1","article-title":"Venetoclax\u2010based combinations in acute myeloid leukemia: current evidence and future directions","volume":"10","author":"Samra B","year":"2020","journal-title":"Front Oncol"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0527-4"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102977"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2603"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.04.008"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3749"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2995","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2995","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:21:22Z","timestamp":1695864082000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/hon.2995"],"URL":"https:\/\/doi.org\/10.1002\/hon.2995","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2995\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2995\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2995\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2995\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2995\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2995\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2995\/v2\/review1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"2021-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}